Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.

BACKGROUND: Hepatocellular carcinoma (HCC) represents the sixteenth most frequent cancer in Argentina. The rise of new therapeutic modalities in intermediate-advanced HCC opens up a new paradigm for the treatment of HCC. AIM: To describe real-life treatments performed in patients with intermediate-advanced HCC before the approval of new systemic options. METHODS: This longitudinal observational cohort study was conducted between 2009 and 2016 in 14 different regional hospitals from Argentina. Included subjects had intermediate-advanced Barcelona Clinic Liver Cancer (BCLC) HCC stages (BCLC B to D). Primary end point analyzed was survival, which was assessed for each BCLC stage from the date of treatment until last patient follow-up or death. Kaplan Meier survival curves and Cox regression analysis were performed, with hazard ratios (HR) calculations and 95% confidence intervals (95%CI). RESULTS: From 327 HCC patients, 41% were BCLC stage B, 20% stage C and 39% stage D. Corresponding median survival were 15 mo (IQR 5-26 mo), 5 mo (IQR 2-13 mo) and 3 mo (IQR 1-13 mo) (P < 0.0001), respectively. Among BCLC-B patients (n = 135), 57% received TACE with a median number of 2 sessions (IQR 1-3 sessions). Survival was significantly better in BCLC-B patients treated with TACE HR = 0.29 (CI: 0.21-0.40) than those without TACE. After tumor reassessment by RECIST 1.1 criteria following the first TACE, patients with complete response achieved longer survival [HR = 0.15 (CI: 0.04-0.56, P = 0.005)]. Eighty-two patients were treated with sorafenib, mostly BCLC-B and C (87.8%). However, 12.2% were BCLC-D. Median survival with sorafenib was 4.5 mo (IQR 2.3-11.7 mo); which was lower among BCLC-D patients 3.2 mo (IQR 2.0-14.1 mo). A total of 36 BCLC-B patients presented tumor progression after TACE. In these patients, treatment with sorafenib presented better survival when compared to those patients who received sorafenib without prior TACE [HR = 0.26 (CI: 0.09-0.71); P = 0.013]. CONCLUSION: In this real setting, our results were lower than expected. This highlights unmet needs in Argentina, prior to the introduction of new treatments for HCC.

Esporotricosis linfocutánea. A propósito de un caso pediátrico / Lymphatic-cutaneous sporotrichosis. A pediatric case

La esporotricosis es la micosis subcutánea más frecuente en Uruguay. Es producida por hongos del complejo Sporothrix. Su reservorio son los restos vegetales y madera en descomposición. En su hábitat natural las condiciones climáticas, temperatura y humedad son variables, pero es inviable a 40°C. Afecta al hombre y animales. Es una enfermedad ocupacional y recreativa, poco frecuente en la edad pediátrica. En nuestro país el modo habitual de adquirirla es a través de arañazos de armadillos (mulitas). La forma clínica clásica y más frecuente de la esporotricosis se caracteriza por un chancro cutáneo de inoculación acompañado de una linfangitis de carácter nodular y troncular. Su evolución tiene un desarrollo subagudo y crónico. A pesar de su signología típica es muchas veces confundida con otras afecciones dermatológicas lo que retarda el diagnóstico. La presentación visceral u osteoarticular es excepcional. El diagnóstico definitivo requiere el aislamiento del hongo en cultivos a partir del sitio de infección. La resolución espontánea es poco común. El tratamiento recomendado es itraconazol administrado durante 3 a 6 meses. También puede utilizarse de manera alternativa yoduro de potasio y la terbinafina. La termoterapia local preconizada por la escuela micológica uruguaya significa muchas veces una valiosa alternativa terapéutica. El objetivo de esta comunicación es la presentación del caso clínico de un niño que cursó una esporotricosis cutáneo-linfática. La misma fue confirmada por estudio micológico y recibió tratamiento con itraconazol y termoterapia local, con buena respuesta.

Sporotrichosis is the most frequent subcutaneous mycosis in Uruguay. It is caused by fungi from the Sporothrix complex. This fungus lives in decaying plant matter, including wood. Climate, temperature and humidity vary in their natural habitat, although they cannot survive when it is hotter than 40°C. It affects both men and animals. Sporotrichosis is an occupational and recreational disease, rather unusual in children. In our country it is usually acquired through armadillo scratches. The classical and most frequent clinical presentation is characterized by a chancre following inoculation, accompanied by nodular and troncular lymphangitis. Evolution of the condition has a subacute and chronic development. In spite of its typical signs, it is often confused with other skin diseases, what delays diagnosis. Visceral or osteoarticular presentation is exceptional. Final diagnosis requires the fungus to be isolated in cultures from the site of the infection. Spontaneous resolution is rather unusual. Itraconazole during 3 to 6 months is the recommended treatment. Alternatively, potassium iodide and terbinafine may be used. Local thermotherapy, recommended by the Uruguayan mycological school often constitutes a valuable therapeutic alternative. This study aims to present the clinical case of a boy with a lymphatic-cutaneous sporotrichosis. The condition was confirmed by mycological studies and he was treated with itraconazole and local thermotherapy, the response being good.